Abstract | BACKGROUND:
Chronic fatigue syndrome is characterized by prolonged and disabling fatigue and a range of neuropsychiatric symptoms including depressed and/or irritable mood. To date, no medical or psychotropic therapies have provided clear symptomatic benefit. METHOD: RESULTS: Fifty-one percent (24/47) of patients receiving moclobemide improved compared with 33% (14/43) of patients receiving placebo (odds ratio = 2.16, 95% confidence interval [CI] = 0.9 to 5.1). Drug response was best characterized symptomatically by an increase in the subjective sense of vigor and energy rather than a reduction in depressed mood. The effect of moclobemide on subjective energy was detectable within the first 2 weeks of treatment and increased across the course of the study. The greatest reduction in clinician-rated disability was in patients with concurrent immunologic dysfunction (mean difference in standardized units of improvement = 0.8, 95% CI = 0.03 to 1.6). CONCLUSION:
|
Authors | I B Hickie, A J Wilson, J M Wright, B K Bennett, D Wakefield, A R Lloyd |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 61
Issue 9
Pg. 643-8
(Sep 2000)
ISSN: 0160-6689 [Print] United States |
PMID | 11030484
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Monoamine Oxidase Inhibitors
- Placebos
- Moclobemide
|
Topics |
- Adult
- Comorbidity
- Depressive Disorder
(drug therapy, epidemiology, psychology)
- Double-Blind Method
- Fatigue Syndrome, Chronic
(drug therapy, epidemiology, psychology)
- Female
- Humans
- Immunity, Cellular
(drug effects)
- Male
- Middle Aged
- Moclobemide
(therapeutic use)
- Monoamine Oxidase Inhibitors
(therapeutic use)
- Placebos
- Stress, Psychological
(drug therapy, epidemiology, psychology)
- Treatment Outcome
|